Press Release
<< Back
Verastem Presents Clinical and Preclinical Data at the 16th World Conference on Lung Cancer
Four oral presentations included results from a Phase 2 clinical trial of VS-6063 (defactinib) in advanced refractory KRAS-Mutated Non-Small Cell Lung Cancer (NSCLC) and presentations on preclinical studies of VS-6063 and VS-5584 in Small-Cell Lung Cancer (SCLC) and Mesothelioma. Two poster presentations detailed trial designs for Verastem’s ongoing COMMAND trial in mesothelioma and Phase 1 dose-escalation study of VS-5584 in advanced solid tumors.
Details and links to the data presentations at WCLC are below:
Oral Presentations
Title: Phase 2 study of
defactinib, VS-6063, a focal adhesion kinase (FAK) inhibitor, in
patients with KRAS mutant non-small cell lung cancer (NSCLC)
Session
info: Mini oral 30: New Kinase Targets; Track: Treatment of Advanced
Diseases – NSCLC
Link to slides from the oral presentation: http://bit.ly/R3M6wc
Title: The cancer stem cell inhibitors VS-6063 (defactinib) and
VS-5584 exhibit synergistic anticancer activity in pre-clinical models
of mesothelioma
Session info: Oral session 40: Biology 1;
Track: Thymoma, Mesothelioma and Other Thoracic Malignancies
Link
to slides from the oral presentation: http://bit.ly/R3M6wc
Title: Targeting Cancer Stem Cells in Small Cell Lung Cancer
Session
info: Mini oral 27: Biology and other issues in SCLC; Track: Small
Cell Lung Cancer
Link to slides from the oral presentation: http://bit.ly/R3M6wc
Title: FAK inhibitor VS-6063 targets mesothelioma cancer stem
cells: Rationale for maintenance therapy after conventional chemotherapy
Session
info: Mini oral 38: Biology and Prognosis; Track: Thymoma,
Mesothelioma and Other Thoracic Malignancies
Link to slides from
the oral presentation: http://bit.ly/R3M6wc
Poster Presentations
Title: COMMAND: A Phase 2 randomized, double-blind, study of
defactinib (VS-6063) as maintenance therapy in malignant pleural
mesothelioma
Poster #: P3.08.014
Session info:
Thymoma, Mesothelioma and Other Thoracic Malignancies – Mesothelioma
Link
to copy of the poster presentation: http://bit.ly/R3M6wc
Title: A Phase 1 dose escalation study of VS-5584, a PI3K/mTOR
inhibitor, administered with VS-6063, a focal adhesion kinase inhibitor,
in mesothelioma
Poster #: P2.08.008
Session info:
Thymoma, Mesothelioma and Other Thoracic Malignancies – Mesothelioma
Link
to copy of the poster presentation: http://bit.ly/R3M6wc
About VS-6063
VS-6063 (defactinib) is an orally available compound designed to target cancer stem cells through the potent inhibition of focal adhesion kinase (FAK). Cancer stem cells are an underlying cause of tumor resistance to chemotherapy, recurrence and ultimate disease progression. Research has demonstrated that FAK activity is critical for the growth and survival of cancer stem cells. VS-6063 is currently being studied in the registration-directed COMMAND trial in mesothelioma (www.COMMANDmeso.com), a “Window of Opportunity” study in patients with mesothelioma prior to surgery, a Phase 1/1b study in combination with paclitaxel in patients with ovarian cancer, a trial in patients with Kras-mutated non-small cell lung cancer and a trial evaluating the combination of VS-6063 and VS-5584 in patients with relapsed mesothelioma. VS-6063 has been granted orphan drug designation for use in mesothelioma in the U.S. and EU.
About VS-5584
VS-5584 is an orally available compound that has demonstrated potent and
highly selective activity against class 1 PI3K enzymes and dual
inhibitory actions against mTORC1 and mTORC2. In preclinical studies,
VS-5584 has been shown to reduce the percentage of cancer stem cells and
induce tumor regression in chemotherapy-resistant models.
About
Forward-looking statements:
This press release includes forward-looking statements about the
Company’s strategy, future plans and prospects, including statements
regarding the development and activity of the Company’s product
candidates, VS-6063and VS-5584, and the Company’s FAK, PI3K/mTOR and
diagnostics programs generally, the structure of our planned or pending
clinical trials and additional planned studies. The words “anticipate,”
“appear,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,”
“predict,” “project,” “target,” “potential,” “will,” “would,” “could,”
“should,” “continue,” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements
contain these identifying words. Each forward-looking statement is
subject to risks and uncertainties that could cause actual results to
differ materially from those expressed or implied in such statement.
Applicable risks and uncertainties include the risks that the
preclinical testing of the Company’s product candidates and preliminary
or interim data from clinical trials may not be predictive of the
results or success of ongoing or later clinical trials, that data may
not be available when we expect it to be, that enrollment of clinical
trials may take longer than expected, that our product candidates will
cause unexpected safety events, that the Company will be unable to
successfully initiate or complete the clinical development of its
product candidates, that the development of the Company’s product
candidates will take longer or cost more than planned, and that the
Company’s product candidates will not receive regulatory approval or
become commercially successful products. Other risks and uncertainties
include those identified under the heading “Risk Factors” in the
Company’s Annual Report on Form 10-K for the year ended
View source version on businesswire.com: http://www.businesswire.com/news/home/20150910005467/en/
Source:
Contact Verastem, Inc.
Brian Sullivan, 781-292-4214
bsullivan@verastem.com
